US 11,744,883 B2
Intradermal combination vaccine against mycoplasma and porcine circovirus
Jordi Montane Giralt, Sant Feliu de Pallerols (ES); Ester Puigvert Molas, Les Preses (ES); Alexandra Moros Sanz, Olot (ES); and Marta Sitjà Arnau, Girona (ES)
Assigned to HIPRA SCIENTIFIC, S.L.U., Amer (ES)
Appl. No. 16/955,015
Filed by HIPRA SCIENTIFIC, S.L.U., Girona (ES)
PCT Filed Dec. 19, 2018, PCT No. PCT/EP2018/085844
§ 371(c)(1), (2) Date Jun. 17, 2020,
PCT Pub. No. WO2019/121916, PCT Pub. Date Jun. 27, 2019.
Claims priority of application No. 17382893 (EP), filed on Dec. 22, 2017.
Prior Publication US 2020/0376106 A1, Dec. 3, 2020
Int. Cl. A61K 39/02 (2006.01); A61K 39/12 (2006.01); A61P 31/20 (2006.01); A61K 9/00 (2006.01); A61K 39/39 (2006.01); A61K 39/00 (2006.01)
CPC A61K 39/0241 (2013.01) [A61K 9/0019 (2013.01); A61K 39/12 (2013.01); A61K 39/39 (2013.01); A61P 31/20 (2018.01); A61K 2039/521 (2013.01); A61K 2039/54 (2013.01); A61K 2039/545 (2013.01); A61K 2039/552 (2013.01); A61K 2039/55566 (2013.01); A61K 2039/70 (2013.01)] 17 Claims
OG exemplary drawing
 
1. A method for the prevention and/or treatment of porcine enzootic pneumonia and/or Porcine Circovirus-Associated Diseases (PCVAD) comprising administering into the dermis of livestock in need thereof a single-dose combination vaccine comprising one or more antigens of Mycoplasma hyopneumoniae, one or more antigens of porcine circovirus, an adjuvant and pharmaceutically acceptable excipients and/or carriers, wherein the one or more antigens of porcine circovirus comprises the PCV2 ORF2 protein in an amount from 0.1 μg/dose to 10 μg/dose.